Cardiogen
Ala-Glu-Asp-Arg / AEDR peptide
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a bioregulator peptide specific to cardiac tissue. It is theorized to normalize gene expression in cardiomyocytes by penetrating cell nuclei and interacting with DNA regulatory sequences. Research applications focus on cardiac tissue repair, prevention of age-related myocardial deterioration, and post-ischemic cardioprotection.
作用机制
Synthetic tetrapeptide bioregulator that targets cardiac tissue. Promotes cardiomyocyte differentiation, enhances cardiac stem cell activity, and may improve myocardial function by modulating gene expression in heart tissue. Part of the Khavinson bioregulator class.
研究协议
仅供研究使用,非医疗建议。
Research protocols (Khavinson method) use 10-20mg orally or sublingually daily for 10-30 day cycles. Sublingual preferred. Cycles repeated every 3-6 months.
研究笔记
Clinical Research Status
Cardiogen has been investigated in clinical studies conducted primarily in Russia, with reports of improved cardiac function markers in elderly patients with age-related cardiovascular deterioration. Studies have examined its use both as a standalone intervention and in combination with other bioregulator peptides as part of comprehensive anti-aging protocols. It is available as a supplement in Russia but has not been evaluated by Western regulatory agencies or subjected to large-scale randomized controlled trials meeting international standards.
Key Published Findings
Research demonstrates that Cardiogen can stimulate proliferation and differentiation of cardiac stem cells in vitro, potentially contributing to myocardial regeneration. Animal studies show reduced infarct size and improved left ventricular function when administered following experimental myocardial ischemia. Gene expression analysis indicates upregulation of cardioprotective factors including heat shock proteins and anti-apoptotic genes in cardiomyocyte cultures exposed to Cardiogen.
Safety Profile
Available literature reports no adverse effects from Cardiogen administration at recommended doses, consistent with the general safety profile of ultrashort bioregulator peptides. Its constituent amino acids (alanine, glutamic acid, aspartic acid, arginine) are all naturally occurring and rapidly metabolized through normal physiological pathways. No contraindications have been formally established, though patients with active cardiac conditions should not use investigational peptides as substitutes for established medical treatments.
Comparison to Related Compounds
Cardiogen is tissue-specific to cardiac muscle, while the related Khavinson peptide Vessels (Lys-Glu-Asp-Trp) targets vascular endothelium, and Thymalin addresses immune function. Unlike BPC-157, which provides general tissue healing through angiogenesis and growth factor modulation, Cardiogen is theorized to work through direct gene regulatory mechanisms specific to cardiomyocytes. Compared to pharmaceutical cardioprotective agents like trimetazidine, Cardiogen represents a fundamentally different approach through peptide bioregulation rather than metabolic modulation.
Community Observations
Users in longevity-focused communities often incorporate Cardiogen as part of broader Khavinson peptide stacks targeting multiple organ systems simultaneously. Reported benefits are generally subtle and difficult to verify without echocardiographic or biomarker monitoring, making subjective assessment challenging. The peptide is typically used in 10-30 day cycles several times per year, following protocols established in Russian gerontological practice.
半衰期
~15-30 minutes
复溶
N/A (typically oral/sublingual capsule)
存储
冻干
Room temperature. Protect from moisture.
复溶后
N/A (oral form)
美国法律状态
又称作
常见问题
什么是 Cardiogen?
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a bioregulator peptide specific to cardiac tissue. It is theorized to normalize gene expression in cardiomyocytes by penetrating cell nuclei and interacting with DNA regulatory sequences. Research applications focus on cardiac tissue repair, prevention of age-related myocardial deterioration, and post-ischemic cardioprotection.
Cardiogen 如何起作用?
Synthetic tetrapeptide bioregulator that targets cardiac tissue. Promotes cardiomyocyte differentiation, enhances cardiac stem cell activity, and may improve myocardial function by modulating gene expression in heart tissue. Part of the Khavinson bioregulator class.
Cardiogen 在美国的监管状态是什么?
Research chemical (not FDA-approved)
Cardiogen 的半衰期是多少?
~15-30 minutes
Cardiogen 还有哪些名称?
Ala-Glu-Asp-Arg, AEDR peptide
Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。
阅读完整免责声明